vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($167.7M vs $158.6M, roughly 1.1× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 19.1%, a 52.1% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 32.4%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-23.6M).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
JRVR vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $167.7M | $158.6M |
| Net Profit | $32.1M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 14.6% | 70.2% |
| Net Margin | 19.1% | 71.2% |
| Revenue YoY | 32.4% | 3661.1% |
| Net Profit YoY | 149.5% | 528.0% |
| EPS (diluted) | $0.59 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $167.7M | — | ||
| Q3 25 | $172.7M | — | ||
| Q2 25 | $174.8M | — | ||
| Q1 25 | $172.3M | $158.6M | ||
| Q4 24 | $126.7M | $22.6M | ||
| Q3 24 | $191.5M | — | ||
| Q2 24 | $188.3M | — | ||
| Q1 24 | $201.1M | — |
| Q4 25 | $32.1M | — | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $9.6M | $112.9M | ||
| Q4 24 | $-64.8M | $-10.5M | ||
| Q3 24 | $-39.4M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $15.4M | — |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 9.3% | 70.2% | ||
| Q4 24 | -57.0% | -60.4% | ||
| Q3 24 | -27.1% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 5.6% | 71.2% | ||
| Q4 24 | -51.1% | -46.4% | ||
| Q3 24 | -20.6% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | $0.59 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $0.16 | $1.90 | ||
| Q4 24 | $-2.44 | $-0.15 | ||
| Q3 24 | $-1.10 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $260.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $538.2M | $350.1M |
| Total Assets | $4.9B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $260.9M | — | ||
| Q3 25 | $238.8M | — | ||
| Q2 25 | $220.0M | — | ||
| Q1 25 | $279.4M | $274.8M | ||
| Q4 24 | $362.3M | $128.0M | ||
| Q3 24 | $359.8M | — | ||
| Q2 24 | $672.5M | — | ||
| Q1 24 | $305.5M | — |
| Q4 25 | $538.2M | — | ||
| Q3 25 | $503.6M | — | ||
| Q2 25 | $492.6M | — | ||
| Q1 25 | $484.5M | $350.1M | ||
| Q4 24 | $460.9M | $229.0M | ||
| Q3 24 | $530.3M | — | ||
| Q2 24 | $541.8M | — | ||
| Q1 24 | $539.5M | — |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.9B | $406.9M | ||
| Q4 24 | $5.0B | $271.6M | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $4.7B | — | ||
| Q1 24 | $5.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.8M | $131.8M |
| Free Cash FlowOCF − Capex | $-23.6M | $131.7M |
| FCF MarginFCF / Revenue | -14.1% | 83.0% |
| Capex IntensityCapex / Revenue | 2.9% | 0.1% |
| Cash ConversionOCF / Net Profit | -0.59× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-17.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.8M | — | ||
| Q3 25 | $34.3M | — | ||
| Q2 25 | $25.2M | — | ||
| Q1 25 | $-51.5M | $131.8M | ||
| Q4 24 | $-247.1M | $-23.2M | ||
| Q3 24 | $-269.9M | — | ||
| Q2 24 | $-8.7M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $33.7M | — | ||
| Q2 25 | $24.7M | — | ||
| Q1 25 | $-52.7M | $131.7M | ||
| Q4 24 | $-252.0M | $-23.2M | ||
| Q3 24 | $-270.8M | — | ||
| Q2 24 | $-9.3M | — | ||
| Q1 24 | $23.3M | — |
| Q4 25 | -14.1% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 14.1% | — | ||
| Q1 25 | -30.6% | 83.0% | ||
| Q4 24 | -198.9% | -102.7% | ||
| Q3 24 | -141.4% | — | ||
| Q2 24 | -4.9% | — | ||
| Q1 24 | 11.6% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | 3.9% | 0.2% | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | -0.59× | — | ||
| Q3 25 | 33.61× | — | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.14× | — | ||
| Q1 24 | 1.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
STOK
Segment breakdown not available.
